Search This Blog

Thursday, February 13, 2020

West Pharmaceutical EPS beats by $0.10, beats on revenue

West Pharmaceutical (NYSE:WST): Q4 Non-GAAP EPS of $0.82 beats by $0.10; GAAP EPS of $0.84 beats by $0.14.
Revenue of $470.6M (+11.4% Y/Y) beats by $19.07M.
https://wordpress.com/post/awesomecapital.wordpress.com/110041

Alkermes EPS beats by $0.17, beats on revenue

Alkermes (NASDAQ:ALKS): Q4 Non-GAAP EPS of $0.83 beats by $0.17; GAAP EPS of -$0.03 misses by $0.37.
Revenue of $412.73M (+30.7% Y/Y) beats by $8.28M.
https://seekingalpha.com/news/3541604-alkermes-eps-beats-0_17-beats-on-revenue

Agios Pharmaceuticals EPS beats by $0.08, beats on revenue

Agios Pharmaceuticals (NASDAQ:AGIO): Q4 GAAP EPS of -$1.60 beats by $0.08.
Revenue of $35.44M (+18.1% Y/Y) beats by $1.72M.
https://seekingalpha.com/news/3541609-agios-pharmaceuticals-eps-beats-0_08-beats-on-revenue

Ironwood Pharmaceuticals EPS beats by $0.07, beats on revenue

Ironwood Pharmaceuticals (NASDAQ:IRWD): Q4 Non-GAAP EPS of $0.30 beats by $0.07; GAAP EPS of $0.30 beats by $0.08.
Revenue of $126.3M (-3.4% Y/Y) beats by $14.24M.
https://seekingalpha.com/news/3541622-ironwood-pharmaceuticals-eps-beats-0_07-beats-on-revenue

Karyopharm Therapeutics EPS misses by $0.08, beats on revenue

Karyopharm Therapeutics (NASDAQ:KPTI): Q4 GAAP EPS of -$0.76 misses by $0.08.
Revenue of $18.1M (+8950.0% Y/Y) beats by $1.83M.
https://seekingalpha.com/news/3541610-karyopharm-therapeutics-eps-misses-0_08-beats-on-revenue

Laboratory Corporation of America EPS beats by $0.06, beats on revenue

Laboratory Corporation of America (NYSE:LH): Q4 Non-GAAP EPS of $2.86 beats by $0.06; GAAP EPS of $2.32 beats by $0.07.
Revenue of $2.95B (+5.7% Y/Y) beats by $30M.
https://seekingalpha.com/news/3541614-laboratory-corporation-of-america-eps-beats-0_06-beats-on-revenue

Blueprint Medicines EPS beats by $0.41, beats on revenue

Blueprint Medicines  (NASDAQ:BPMC): Q4 GAAP EPS of -$1.35 beats by $0.41.
Revenue of $51.53M (+4902.9% Y/Y) beats by $25.53M.
https://seekingalpha.com/news/3541618-blueprint-medicines-and-nbsp-eps-beats-0_41-beats-on-revenue